490 lines
33 KiB
HTML
490 lines
33 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="zh-CN">
|
||
<head>
|
||
<meta charset="UTF-8">
|
||
<meta name="viewport" content="width=device-width, initial-scale=1.0">
|
||
<title>减肥药 - 深度行业研究报告</title>
|
||
|
||
<!-- Tailwind CSS & DaisyUI -->
|
||
<script src="https://cdn.tailwindcss.com"></script>
|
||
<link href="https://cdn.jsdelivr.net/npm/daisyui@4.11.1/dist/full.min.css" rel="stylesheet" type="text/css" />
|
||
|
||
<!-- Alpine.js -->
|
||
<script defer src="https://cdn.jsdelivr.net/npm/alpinejs@3.x.x/dist/cdn.min.js"></script>
|
||
|
||
<!-- ECharts -->
|
||
<script src="https://cdn.jsdelivr.net/npm/echarts@5.5.0/dist/echarts.min.js"></script>
|
||
|
||
<!-- Google Fonts -->
|
||
<link rel="preconnect" href="https://fonts.googleapis.com">
|
||
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
|
||
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&family=Space+Grotesk:wght@400;500;700&display=swap" rel="stylesheet">
|
||
|
||
<style>
|
||
:root {
|
||
--glow-color-1: rgba(168, 85, 247, 0.2); /* purple */
|
||
--glow-color-2: rgba(59, 130, 246, 0.2); /* blue */
|
||
--glow-color-3: rgba(20, 184, 166, 0.15); /* teal */
|
||
}
|
||
|
||
html {
|
||
scroll-behavior: smooth;
|
||
}
|
||
|
||
body {
|
||
font-family: 'Inter', sans-serif;
|
||
background-color: #02040a;
|
||
color: #e2e8f0;
|
||
overflow-x: hidden;
|
||
position: relative;
|
||
}
|
||
|
||
body::before {
|
||
content: '';
|
||
position: fixed;
|
||
top: -20%;
|
||
left: -20%;
|
||
width: 80vw;
|
||
height: 80vh;
|
||
background: radial-gradient(circle, var(--glow-color-1) 0%, rgba(10, 10, 15, 0) 70%);
|
||
filter: blur(100px);
|
||
z-index: -1;
|
||
animation: pulse-glow-1 15s infinite alternate;
|
||
}
|
||
|
||
body::after {
|
||
content: '';
|
||
position: fixed;
|
||
bottom: -30%;
|
||
right: -20%;
|
||
width: 90vw;
|
||
height: 90vh;
|
||
background: radial-gradient(circle, var(--glow-color-2) 0%, rgba(10, 10, 15, 0) 70%);
|
||
filter: blur(120px);
|
||
z-index: -1;
|
||
animation: pulse-glow-2 18s infinite alternate;
|
||
}
|
||
|
||
@keyframes pulse-glow-1 {
|
||
from { transform: scale(0.8) translate(5%, 5%); opacity: 0.7; }
|
||
to { transform: scale(1.2) translate(-5%, -5%); opacity: 1; }
|
||
}
|
||
|
||
@keyframes pulse-glow-2 {
|
||
from { transform: scale(1.2) translate(-5%, -5%); opacity: 1; }
|
||
to { transform: scale(0.9) translate(5%, 5%); opacity: 0.7; }
|
||
}
|
||
|
||
.glass-card {
|
||
background: rgba(17, 24, 39, 0.3);
|
||
backdrop-filter: blur(20px);
|
||
-webkit-backdrop-filter: blur(20px);
|
||
border: 1px solid rgba(255, 255, 255, 0.1);
|
||
transition: all 0.3s ease;
|
||
}
|
||
|
||
.glass-card:hover {
|
||
border-color: rgba(255, 255, 255, 0.2);
|
||
transform: translateY(-5px);
|
||
box-shadow: 0 20px 30px rgba(0,0,0,0.2);
|
||
}
|
||
|
||
.fui-title {
|
||
font-family: 'Space Grotesk', sans-serif;
|
||
text-shadow: 0 0 8px rgba(59, 130, 246, 0.5);
|
||
}
|
||
|
||
.fui-header {
|
||
font-family: 'Space Grotesk', sans-serif;
|
||
letter-spacing: 0.05em;
|
||
}
|
||
|
||
/* Custom table styling */
|
||
.glass-table {
|
||
background-color: transparent;
|
||
}
|
||
.glass-table th {
|
||
background-color: rgba(31, 41, 55, 0.3);
|
||
color: #9ca3af;
|
||
font-family: 'Space Grotesk', sans-serif;
|
||
letter-spacing: 0.1em;
|
||
text-transform: uppercase;
|
||
font-size: 0.75rem;
|
||
border-bottom: 1px solid rgba(255, 255, 255, 0.1);
|
||
}
|
||
.glass-table td, .glass-table th {
|
||
padding: 1rem 1.5rem;
|
||
}
|
||
.glass-table tr {
|
||
transition: background-color 0.2s ease;
|
||
border-bottom: 1px solid rgba(255, 255, 255, 0.05);
|
||
}
|
||
.glass-table tr:last-child {
|
||
border-bottom: none;
|
||
}
|
||
.glass-table tbody tr:hover {
|
||
background-color: rgba(30, 41, 55, 0.5);
|
||
}
|
||
</style>
|
||
</head>
|
||
|
||
<body class="min-h-screen">
|
||
<div class="max-w-7xl mx-auto p-4 sm:p-6 lg:p-8 space-y-12">
|
||
|
||
<!-- Header -->
|
||
<header class="text-center space-y-4 pt-16 pb-8">
|
||
<h1 class="fui-title text-5xl md:text-7xl font-bold bg-clip-text text-transparent bg-gradient-to-br from-white to-slate-400">
|
||
减肥药
|
||
</h1>
|
||
<p class="fui-header text-lg md:text-xl text-slate-400">深度行业研究报告</p>
|
||
<div class="pt-4 text-xs text-slate-500">
|
||
<p>北京价值前沿科技有限公司 AI投研agent：“价小前投研” 进行投研呈现</p>
|
||
<p>本报告为AI合成数据，投资需谨慎。</p>
|
||
</div>
|
||
</header>
|
||
|
||
<!-- Insight Core -->
|
||
<section id="insight" class="space-y-8">
|
||
<h2 class="fui-header text-3xl font-bold text-center text-cyan-300 tracking-wider">核心洞察 (Core Insight)</h2>
|
||
|
||
<!-- Bento Grid Layout -->
|
||
<div class="grid grid-cols-1 lg:grid-cols-3 gap-6">
|
||
<!-- Core Logic & Market Perception -->
|
||
<div class="glass-card rounded-3xl p-6 lg:col-span-2 lg:row-span-2 space-y-6">
|
||
<h3 class="fui-header text-xl font-semibold text-violet-300">核心逻辑与市场认知</h3>
|
||
<div class="text-slate-300 space-y-4 text-sm leading-relaxed">
|
||
<p><strong class="text-slate-100">核心驱动力：</strong>支撑减肥药概念的根本逻辑是“科技突破+巨大市场”的经典组合。以司美格鲁肽和替尔泊肽为代表的GLP-1类药物，实现了15%-20%甚至更高的体重减轻，疗效远超以往，接近减重手术，具有革命性。同时，全球肥胖人口基数庞大且持续增长，当前市场“需求远超供给”。国家卫健委首次印发《肥胖症诊疗指南（2024年版）》，也从政策层面承认了肥胖的疾病属性和治疗的必要性。</p>
|
||
<p><strong class="text-slate-100">市场热度与情绪：</strong>市场关注度极高，情绪呈现“整体乐观，但分歧加剧”的特点。乐观情绪源于千亿美金级的市场空间、巨头并购大战及股价表现。分歧与谨慎则源于：1）口服药研发受挫（辉瑞失败、礼来数据不及预期），凸显高技术门槛；2）价格战与医保压力（巨头主动降价、中国专利悬崖预警）；3）长期安全性与副作用（肌肉流失、胃肠道反应）的担忧。</p>
|
||
<p><strong class="text-slate-100">综合结论：</strong>减肥药概念已从纯粹炒作预期的阶段，进入基本面驱动和逻辑验证期。龙头企业的商业化能力、后发企业的差异化创新能力、以及上游产业链的订单兑现能力，将成为决定未来价值的核心。这是一个长坡厚雪的赛道，但淘汰赛已经开始。</p>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Expectation Gap Analysis -->
|
||
<div class="glass-card rounded-3xl p-6 space-y-4">
|
||
<h3 class="fui-header text-xl font-semibold text-violet-300">预期差分析</h3>
|
||
<ul class="list-disc list-inside text-slate-300 space-y-2 text-sm">
|
||
<li><strong class="text-slate-100">从“唯效果论”到“综合体验为王”：</strong>市场普遍关注减重百分比，但潜在关键点是“减肥质量”（保肌减脂）和耐受性。布局“减脂增肌”新机制的公司（如来凯医药）可能在差异化竞争中胜出。</li>
|
||
<li><strong class="text-slate-100">中国市场是“蓝海”还是“红海”：</strong>市场认知潜力巨大，但现实是支付能力、文化偏好和较短的实际疗程构成挑战。2026年专利到期后，仿制药涌入将迅速将市场变为红海。</li>
|
||
<li><strong class="text-slate-100">对口服药的过度乐观：</strong>市场期待口服药颠覆注射剂，但辉瑞的失败和礼来的数据回落表明，在实现高疗效同时控制副作用是巨大挑战，市场期待可能过于超前。</li>
|
||
</ul>
|
||
</div>
|
||
|
||
<!-- Key Catalysts -->
|
||
<div class="glass-card rounded-3xl p-6 space-y-4">
|
||
<h3 class="fui-header text-xl font-semibold text-violet-300">关键催化剂</h3>
|
||
<ul class="list-disc list-inside text-slate-300 space-y-2 text-sm">
|
||
<li><strong class="text-slate-100">近期临床数据披露：</strong>关注ADA等学术会议上，礼来、来凯医药、众生药业、博瑞医药等国内外企业的关键II/III期数据。</li>
|
||
<li><strong class="text-slate-100">国内新品上市与销售放量：</strong>信达生物玛仕度肽作为首个国产创新双靶药，其初期销售数据是验证市场需求的关键。</li>
|
||
<li><strong class="text-slate-100">海外巨头BD动态：</strong>国际巨头口服药进展不顺可能加速对国内优质管线的BD（商务拓展）。</li>
|
||
</ul>
|
||
</div>
|
||
|
||
<!-- Concept Events Timeline -->
|
||
<div class="glass-card rounded-3xl p-6 lg:col-span-3 space-y-4">
|
||
<h3 class="fui-header text-xl font-semibold text-violet-300">概念发展路径</h3>
|
||
<div id="timeline-chart" style="width: 100%; height: 300px;"></div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Detailed Data Tabs -->
|
||
<section id="data-details" x-data="{ tab: 'news' }" class="space-y-8">
|
||
<h2 class="fui-header text-3xl font-bold text-center text-cyan-300 tracking-wider">多维数据透视</h2>
|
||
|
||
<div class="glass-card rounded-2xl p-2 max-w-lg mx-auto">
|
||
<div class="tabs tabs-boxed justify-center bg-transparent">
|
||
<a class="tab tab-lg" :class="{'tab-active !bg-blue-600/50 text-white': tab === 'news'}" @click.prevent="tab = 'news'">新闻</a>
|
||
<a class="tab tab-lg" :class="{'tab-active !bg-purple-600/50 text-white': tab === 'roadshow'}" @click.prevent="tab = 'roadshow'">路演</a>
|
||
<a class="tab tab-lg" :class="{'tab-active !bg-teal-600/50 text-white': tab === 'research'}" @click.prevent="tab = 'research'">研报</a>
|
||
</div>
|
||
</div>
|
||
|
||
<div class="glass-card rounded-3xl p-6 min-h-[500px]">
|
||
<!-- News Content -->
|
||
<div x-show="tab === 'news'" x-transition>
|
||
<div class="prose prose-invert max-w-none prose-sm prose-p:text-slate-300 prose-h4:text-violet-300 prose-strong:text-slate-100">
|
||
<h4>市场格局与竞争</h4>
|
||
<ul>
|
||
<li><strong>双寡头与新进入者：</strong>市场由诺和诺德与礼来主导，但辉瑞（收购Metsera）、罗氏（收购Carmot）等巨头正通过并购进入，竞争加剧。诺华明确表示不参与“狂潮”。</li>
|
||
<li><strong>需求与趋势：</strong>市场需求持续高速增长，尤其对疗效更佳的口服产品需求迫切。GLP-1药物因头部公司降价，市场渗透率有望提升。</li>
|
||
<li><strong>价格战初现：</strong>礼来将Zepbound价格下调至$349-$499/月，诺和诺德将Wegovy现金支付价降至$499/月（原价约$1349）。</li>
|
||
</ul>
|
||
<h4>主要公司动态</h4>
|
||
<ul>
|
||
<li><strong>礼来(Lilly)：</strong>销售强劲，但Q3因减肥药销售不及预期。Zepbound有望明年在日本获批。口服药orforglipron三期数据不及预期（72周减重11.2%）。</li>
|
||
<li><strong>诺和诺德(Novo Nordisk)：</strong>Wegovy Q2销售额飙升67%。口服司美格鲁肽在中国获批上市。研究显示Ozempic可能降低老年痴呆症风险。司美中国区2024年销售目标未完全达成。</li>
|
||
<li><strong>辉瑞(Pfizer)：</strong>以潜在总价73亿美元收购Metsera，正式入局减肥药赛道。</li>
|
||
<li><strong>中国公司：</strong>信达生物、博瑞医药等创新药企受关注。诺泰生物、圣诺生物等上游供应链企业受益。</li>
|
||
</ul>
|
||
<h4>监管与政策</h4>
|
||
<ul>
|
||
<li><strong>中国：</strong>国家卫健委印发国内首部《肥胖症诊疗指南（2024年版）》。</li>
|
||
<li><strong>美国：</strong>FDA默许在药品短缺时配药师提供仿制药，礼来对此发出律师函。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Roadshow Content -->
|
||
<div x-show="tab === 'roadshow'" x-transition style="display: none;">
|
||
<div class="prose prose-invert max-w-none prose-sm prose-p:text-slate-300 prose-h4:text-violet-300 prose-strong:text-slate-100">
|
||
<h4>行业逻辑与趋势</h4>
|
||
<ul>
|
||
<li><strong>核心赛道：</strong>减肥药被视为2024年医药核心主题投资机会，海外映射效应持续提振国内标的。</li>
|
||
<li><strong>研发方向：</strong>五大方向为主：安全性提升、差异化减脂（保肌）、长效化（月制剂）、降低停药反弹、口服药开发。口服药明确为未来主流，但研发难度高于预期。</li>
|
||
<li><strong>肌肉流失痛点：</strong>GLP-1药物存在肌肉流失副作用（约40%减重来自肌肉），易导致体重反弹。市场亟需“增肌减脂”类药物提升减肥质量。</li>
|
||
</ul>
|
||
<h4>中美市场分析</h4>
|
||
<ul>
|
||
<li><strong>美国市场：</strong>2026年起Medicare强制价格谈判将使药价大幅下降（55-70%），但新增覆盖人群足以支撑千亿美元峰值销售。</li>
|
||
<li><strong>中国市场：</strong>2025年减重市场规模预计65-70亿元。2026年是关键变量，司美格鲁肽专利到期、医保谈判、仿制药（≥6家）入场将引发价格战，价格带可能下移30-50%，市场有望破百亿但竞争白热化。</li>
|
||
</ul>
|
||
<h4>关键公司与产品</h4>
|
||
<ul>
|
||
<li><strong>礼来/诺和诺德：</strong>全球双寡头，需求远超供给，全力扩产。礼来替尔泊肽中国III期数据积极；口服药Orforglipron三期数据不及预期，为BD提供窗口。</li>
|
||
<li><strong>辉瑞：</strong>收购的Mancilla（一月一次注射）2A数据理想，成为2026年最具催化潜力管线。</li>
|
||
<li><strong>国内企业：</strong>信达玛仕度肽已获批；博瑞、众生等III期进行中；华东、恒瑞等布局口服小分子；歌礼制药AC30口服药早期数据显示无呕吐优势；康缘药业双靶点GLP-1安全性数据良好，具BD潜力。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Research Report Content -->
|
||
<div x-show="tab === 'research'" x-transition style="display: none;">
|
||
<div class="prose prose-invert max-w-none prose-sm prose-p:text-slate-300 prose-h4:text-violet-300 prose-strong:text-slate-100">
|
||
<h4>市场潜力与挑战</h4>
|
||
<ul>
|
||
<li><strong>中国市场：</strong>潜力巨大，预计2030年市场规模达109亿美元。但面临文化偏好（62%消费者倾向锻炼节食）和医保支付限制的挑战。</li>
|
||
<li><strong>全球动态：</strong>减肥药已成全球MNC必争之地。辉瑞因肝损伤风险终止Danuglipron开发，礼来Orforglipron III期成功，即将成为首个上市的口服小分子GLP-1激动剂。</li>
|
||
</ul>
|
||
<h4>技术进展与方向</h4>
|
||
<ul>
|
||
<li><strong>下一代药物：</strong>诺和诺德新型口服药Amycretin，一期数据显示12周减重13.1%，效果惊人。</li>
|
||
<li><strong>差异化创新：</strong>中国药企围绕长效化、口服小分子、双/三靶点、增肌减脂新机制（如ActRII通路）进行创新布局。</li>
|
||
<li><strong>政策指引：</strong>世界卫生组织（WHO）计划于2025年出台GLP-1药物使用指南，将推动规范化应用。</li>
|
||
</ul>
|
||
<h4>产业链机遇</h4>
|
||
<ul>
|
||
<li><strong>直接受益：</strong>信达生物（创新药）、药明康德（CDMO龙头）等。</li>
|
||
<li><strong>API/CDMO：</strong>凯莱英、诺泰生物、圣诺生物等供应商/CDMO企业受益于全球需求。</li>
|
||
<li><strong>上游试剂：</strong>昊帆生物、金凯生科等辅料供应商亦将受益。</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Industry Chain -->
|
||
<section id="industry-chain" class="space-y-8">
|
||
<h2 class="fui-header text-3xl font-bold text-center text-cyan-300 tracking-wider">产业链深度剖析</h2>
|
||
<div class="grid grid-cols-1 md:grid-cols-3 gap-6 text-sm">
|
||
<!-- Upstream -->
|
||
<div class="glass-card rounded-3xl p-6 space-y-3">
|
||
<h3 class="fui-header text-lg font-semibold text-center text-blue-300">上游：卖水者 (高确定性)</h3>
|
||
<p class="text-center text-slate-400">提供原料、试剂及研发生产外包服务，深度绑定全球供应链。</p>
|
||
<div class="divider before:bg-blue-300/20 after:bg-blue-300/20"></div>
|
||
<ul class="list-disc list-inside space-y-2 text-slate-300">
|
||
<li><strong>原料与试剂:</strong> 金凯生科, 昊帆生物</li>
|
||
<li><strong>多肽原料药 (API):</strong> 诺泰生物, 圣诺生物, 翰宇药业</li>
|
||
<li><strong>CRO/CDMO:</strong> 药明康德, 凯莱英, 博济医药</li>
|
||
</ul>
|
||
</div>
|
||
<!-- Midstream -->
|
||
<div class="glass-card rounded-3xl p-6 space-y-3">
|
||
<h3 class="fui-header text-lg font-semibold text-center text-purple-300">中游：淘金者 (高弹性)</h3>
|
||
<p class="text-center text-slate-400">自主研发GLP-1类及新机制减肥药，或进行仿制。</p>
|
||
<div class="divider before:bg-purple-300/20 after:bg-purple-300/20"></div>
|
||
<ul class="list-disc list-inside space-y-2 text-slate-300">
|
||
<li><strong>创新药企:</strong> 恒瑞医药, 信达生物, 博瑞医药, 众生药业, 来凯医药</li>
|
||
<li><strong>仿制/类似药企:</strong> 华东医药, 通化东宝</li>
|
||
</ul>
|
||
</div>
|
||
<!-- Downstream -->
|
||
<div class="glass-card rounded-3xl p-6 space-y-3">
|
||
<h3 class="fui-header text-lg font-semibold text-center text-teal-300">下游：分销与服务</h3>
|
||
<p class="text-center text-slate-400">负责药品流通环节，连接药企与终端消费者。</p>
|
||
<div class="divider before:bg-teal-300/20 after:bg-teal-300/20"></div>
|
||
<ul class="list-disc list-inside space-y-2 text-slate-300">
|
||
<li>药品分销商</li>
|
||
<li>零售药店</li>
|
||
<li>数字医疗平台</li>
|
||
</ul>
|
||
</div>
|
||
</div>
|
||
</section>
|
||
|
||
<!-- Stock Data -->
|
||
<section id="stock-data" class="space-y-8">
|
||
<h2 class="fui-header text-3xl font-bold text-center text-cyan-300 tracking-wider">相关标的梳理</h2>
|
||
|
||
<!-- Stocks Table -->
|
||
<div class="glass-card rounded-3xl p-4 sm:p-6 overflow-x-auto">
|
||
<div class="space-y-6">
|
||
<div>
|
||
<h4 class="fui-header text-lg font-semibold text-violet-300 mb-4">创新药企</h4>
|
||
<table class="table w-full glass-table">
|
||
<thead><tr><th>股票名称</th><th>股票代码</th><th>核心逻辑</th></tr></thead>
|
||
<tbody>
|
||
<tr><td>常山药业</td><td><a href="https://valuefrontier.cn/company?scode=300255" target="_blank" class="link link-hover text-cyan-400">300255</a></td><td>艾本那肽现场核查完成</td></tr>
|
||
<tr><td>华森制药</td><td><a href="https://valuefrontier.cn/company?scode=002907" target="_blank" class="link link-hover text-cyan-400">002907</a></td><td>创新药布局</td></tr>
|
||
<tr><td>科源制药</td><td><a href="https://valuefrontier.cn/company?scode=301281" target="_blank" class="link link-hover text-cyan-400">301281</a></td><td>创新药布局</td></tr>
|
||
<tr><td>恒瑞医药</td><td><a href="https://valuefrontier.cn/company?scode=600276" target="_blank" class="link link-hover text-cyan-400">600276</a></td><td>布局口服小分子HRS-7535、双靶点HRS-9531</td></tr>
|
||
<tr><td>众生药业</td><td><a href="https://valuefrontier.cn/company?scode=002317" target="_blank" class="link link-hover text-cyan-400">002317</a></td><td>GLP-1/GIP双靶点RAY1225 II期数据亮眼</td></tr>
|
||
<tr><td>博瑞医药</td><td><a href="https://valuefrontier.cn/company?scode=688166" target="_blank" class="link link-hover text-cyan-400">688166</a></td><td>GLP-1/GIP双靶点BGM-0504进入临床III期</td></tr>
|
||
<tr><td>信立泰</td><td><a href="https://valuefrontier.cn/company?scode=002294" target="_blank" class="link link-hover text-cyan-400">002294</a></td><td>创新药布局</td></tr>
|
||
<tr><td>乐普医疗</td><td><a href="https://valuefrontier.cn/company?scode=300003" target="_blank" class="link link-hover text-cyan-400">300003</a></td><td>布局口服多肽管线</td></tr>
|
||
<tr><td>甘李药业</td><td><a href="https://valuefrontier.cn/company?scode=603087" target="_blank" class="link link-hover text-cyan-400">603087</a></td><td>长效GLP-1激动剂GZR18处于临床2a期</td></tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
<div>
|
||
<h4 class="fui-header text-lg font-semibold text-violet-300 mb-4">仿制药/生物类似药企</h4>
|
||
<table class="table w-full glass-table">
|
||
<thead><tr><th>股票名称</th><th>股票代码</th><th>相关药物</th></tr></thead>
|
||
<tbody>
|
||
<tr><td>华东医药</td><td><a href="https://valuefrontier.cn/company?scode=000963" target="_blank" class="link link-hover text-cyan-400">000963</a></td><td>利拉鲁肽、司美格鲁肽类似药、口服小分子</td></tr>
|
||
<tr><td>翰宇药业</td><td><a href="https://valuefrontier.cn/company?scode=300199" target="_blank" class="link link-hover text-cyan-400">300199</a></td><td>利拉鲁肽、司美格鲁肽、替尔泊肽</td></tr>
|
||
<tr><td>通化东宝</td><td><a href="https://valuefrontier.cn/company?scode=600867" target="_blank" class="link link-hover text-cyan-400">600867</a></td><td>利拉鲁肽</td></tr>
|
||
<tr><td>丽珠集团</td><td><a href="https://valuefrontier.cn/company?scode=000513" target="_blank" class="link link-hover text-cyan-400">000513</a></td><td>司美格鲁肽</td></tr>
|
||
<tr><td>双鹭药业</td><td><a href="https://valuefrontier.cn/company?scode=002038" target="_blank" class="link link-hover text-cyan-400">002038</a></td><td>利拉鲁肽</td></tr>
|
||
<tr><td>凯因科技</td><td><a href="https://valuefrontier.cn/company?scode=688687" target="_blank" class="link link-hover text-cyan-400">688687</a></td><td>利拉鲁肽</td></tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
<div>
|
||
<h4 class="fui-header text-lg font-semibold text-violet-300 mb-4">上游产业链 (原料/CDMO)</h4>
|
||
<table class="table w-full glass-table">
|
||
<thead><tr><th>股票名称</th><th>股票代码</th><th>业务环节</th></tr></thead>
|
||
<tbody>
|
||
<tr><td>诺泰生物</td><td>-</td><td>替尔泊肽/多肽原料药</td></tr>
|
||
<tr><td>圣诺生物</td><td><a href="https://valuefrontier.cn/company?scode=688117" target="_blank" class="link link-hover text-cyan-400">688117</a></td><td>多肽原料药 / CDMO</td></tr>
|
||
<tr><td>金凯生科</td><td><a href="https://valuefrontier.cn/company?scode=301509" target="_blank" class="link link-hover text-cyan-400">301509</a></td><td>中间体</td></tr>
|
||
<tr><td>昊帆生物</td><td><a href="https://valuefrontier.cn/company?scode=301393" target="_blank" class="link link-hover text-cyan-400">301393</a></td><td>试剂</td></tr>
|
||
<tr><td>药明康德</td><td><a href="https://valuefrontier.cn/company?scode=603259" target="_blank" class="link link-hover text-cyan-400">603259</a></td><td>CRO / CDMO</td></tr>
|
||
<tr><td>凯莱英</td><td><a href="https://valuefrontier.cn/company?scode=002821" target="_blank" class="link link-hover text-cyan-400">002821</a></td><td>CRO / CDMO</td></tr>
|
||
<tr><td>博济医药</td><td><a href="https://valuefrontier.cn/company?scode=300404" target="_blank" class="link link-hover text-cyan-400">300404</a></td><td>CRO / CDMO</td></tr>
|
||
<tr><td>奥锐特</td><td><a href="https://valuefrontier.cn/company?scode=605116" target="_blank" class="link link-hover text-cyan-400">605116</a></td><td>多肽原料药</td></tr>
|
||
</tbody>
|
||
</table>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
<!-- Rise Analysis -->
|
||
<div class="glass-card rounded-3xl p-4 sm:p-6">
|
||
<h4 class="fui-header text-lg font-semibold text-violet-300 mb-4">历史涨幅归因分析</h4>
|
||
<div class="grid grid-cols-1 md:grid-cols-2 gap-4">
|
||
<div class="glass-card rounded-2xl p-4 space-y-2 text-sm">
|
||
<div class="flex justify-between items-baseline">
|
||
<h5 class="font-bold text-base text-slate-100">康缘药业 (600557)</h5>
|
||
<span class="badge badge-success badge-outline">+9.97% (2025-06-11)</span>
|
||
</div>
|
||
<p class="text-slate-300">涨停主要受减肥药和创新药概念驱动，公司在减肥药领域有双靶点、三靶点GLP-1管线布局，若II期数据显示良好安全性，具备对外BD潜力。</p>
|
||
</div>
|
||
<div class="glass-card rounded-2xl p-4 space-y-2 text-sm">
|
||
<h5 class="font-bold text-base text-slate-100">百花医药 (600721)</h5>
|
||
<span class="badge badge-success badge-outline">+10.03% (2025-08-18)</span>
|
||
<p class="text-slate-300">上涨受整个减肥药板块强势表现带动，直接催化剂为FDA加速批准Wegovy用于治疗MASH的新适应症，提升了市场对GLP-1类药物的关注度。</p>
|
||
</div>
|
||
<div class="glass-card rounded-2xl p-4 space-y-2 text-sm">
|
||
<h5 class="font-bold text-base text-slate-100">美诺华 (603538)</h5>
|
||
<span class="badge badge-success badge-outline">+10.02% (2025-06-23)</span>
|
||
<p class="text-slate-300">受益于减肥药行业利好（美国指南将新药列为一线治疗），叠加公司布局GLP-1类药物（司美格鲁肽中间体已获订单）及合成生物学概念。</p>
|
||
</div>
|
||
<div class="glass-card rounded-2xl p-4 space-y-2 text-sm">
|
||
<h5 class="font-bold text-base text-slate-100">ST诺泰 (688076)</h5>
|
||
<span class="badge badge-success badge-outline">+5.31% (2025-09-15)</span>
|
||
<p class="text-slate-300">上涨由行业利好（诺和诺德amylin管线数据预期）驱动，公司在GLP-1多肽原料药领域有重要布局，并与多家头部仿制药企合作。</p>
|
||
</div>
|
||
</div>
|
||
</div>
|
||
|
||
</section>
|
||
|
||
</div>
|
||
|
||
<script>
|
||
document.addEventListener('DOMContentLoaded', function () {
|
||
var chartDom = document.getElementById('timeline-chart');
|
||
var myChart = echarts.init(chartDom, 'dark');
|
||
var option;
|
||
|
||
option = {
|
||
backgroundColor: 'transparent',
|
||
tooltip: {
|
||
trigger: 'axis',
|
||
formatter: function (params) {
|
||
const data = params[0].data;
|
||
return `<b>${data.period} (${data.year})</b><br/>${data.event}`;
|
||
},
|
||
backgroundColor: 'rgba(17, 24, 39, 0.8)',
|
||
borderColor: 'rgba(255, 255, 255, 0.2)',
|
||
textStyle: {
|
||
color: '#e2e8f0'
|
||
}
|
||
},
|
||
grid: {
|
||
left: '3%',
|
||
right: '4%',
|
||
bottom: '3%',
|
||
containLabel: true
|
||
},
|
||
xAxis: {
|
||
type: 'category',
|
||
data: ['技术奠基', '全球热潮', '商业化落地', '未来关键节点'],
|
||
axisLine: { lineStyle: { color: 'rgba(255, 255, 255, 0.2)' } },
|
||
axisLabel: { color: '#9ca3af', fontFamily: 'Space Grotesk' },
|
||
},
|
||
yAxis: {
|
||
type: 'value',
|
||
show: false
|
||
},
|
||
series: [
|
||
{
|
||
name: '发展阶段',
|
||
type: 'line',
|
||
symbol: 'circle',
|
||
symbolSize: 10,
|
||
smooth: true,
|
||
itemStyle: {
|
||
color: '#a855f7' // purple
|
||
},
|
||
lineStyle: {
|
||
width: 3,
|
||
color: {
|
||
type: 'linear',
|
||
x: 0, y: 0, x2: 1, y2: 0,
|
||
colorStops: [{
|
||
offset: 0, color: '#a855f7'
|
||
}, {
|
||
offset: 1, color: '#3b82f6'
|
||
}]
|
||
},
|
||
shadowColor: 'rgba(168, 85, 247, 0.5)',
|
||
shadowBlur: 10
|
||
},
|
||
areaStyle: {
|
||
color: new echarts.graphic.LinearGradient(0, 0, 0, 1, [{
|
||
offset: 0,
|
||
color: 'rgba(168, 85, 247, 0.3)'
|
||
}, {
|
||
offset: 1,
|
||
color: 'rgba(10, 10, 15, 0)'
|
||
}])
|
||
},
|
||
data: [
|
||
{ value: 1, year: '<2023', period: '技术奠基期', event: '司美/替尔泊肽获批降糖适应症，减重副作用引关注。' },
|
||
{ value: 2, year: '2024', period: '全球热潮期', event: '巨头并购（辉瑞/罗氏），诺和诺德公布新药Amycretin惊人数据。' },
|
||
{ value: 3, year: '2025', period: '商业化落地期', event: '价格战初现，国产新药（玛仕度肽）获批，WHO将出台指南。' },
|
||
{ value: 4, year: '2026+', period: '预期修正期', event: '司美中国专利到期，仿制药竞争白热化，美国Medicare开始价格谈判。' }
|
||
]
|
||
}
|
||
]
|
||
};
|
||
|
||
myChart.setOption(option);
|
||
window.addEventListener('resize', function() {
|
||
myChart.resize();
|
||
});
|
||
});
|
||
</script>
|
||
</body>
|
||
</html> |